Radius is a commercial-stage biopharmaceutical company headquartered in Boston, and it focuses on addressing unmet needs in bone health and neuro-orphan diseases. Its lead product, Tymlos was launched in the U.S. in 2017 for the treatment of postmenopausal osteoporosis patients at a high risk of fracture.
Terms of the deal included $10 per share in cash, plus one nontransferable contingent value right per share, representing the contractual right to receive $1 per share in cash, payable upon Tymlos net sales reaching $300 million during any consecutive 12-month period prior to Dec. 31, 2025.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
